The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target and indication from rival innovator companies, not copycat products with identical CAR sequences. In such a market, sequence-limited composition-of-matter protection of the CAR sequence may have limited value. We are now seeing this play out at the UPC, with